We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
JAKAVI Novartis Pharmaceuticals Australia Pty Ltd
Product name
JAKAVI
Accepted date
Nov-2025
Active ingredients
ruxolitinib phosphate
Proposed indication
Jakavi (ruxolitinib) is proposed for the treatment of patients aged 28 days and older with acute graft-versus-host disease who have inadequate response to corticosteroids and for the treatment of patients aged 6 months and older with chronic graft-versus-host disease who have inadequate response to corticosteroids.
Application type
C (new indication)
Publication date
Nov-2025